CR Holroyd, R Seth, M Bukhari, A Malaviya… - …, 2019 - academic.oup.com
Christopher R. Holroyd1, Rakhi Seth1, Marwan Bukhari2, Anshuman Malaviya3, Claire Holmes1, Elizabeth Curtis4, Christopher Chan1, Mohammed A. Yusuf3, Anna Litwic4, 5 …
Objectives. To evaluate the risk of serious infections (SIs) in patients with RA treated with anti-TNF therapy with emphasis on the risk across different ages. Methods. Using data from …
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and …
Objectives. To assess the proportion of RA patients who discontinued biologics in world registries and health care databases and to identify causes and predictors of …
Background Elderly patients represent an increasing proportion of the inflammatory bowel disease (IBD) population. Aim To critically review available data regarding the care of …
NZ Borren, AN Ananthakrishnan - Clinical gastroenterology and hepatology, 2019 - Elsevier
Background & Aims Management of immune-mediated inflammatory diseases often requires lifelong immunosuppression. Increasing numbers of older patients have inflammatory …
AMH Boots, AB Maier, P Stinissen, P Masson… - Nature Reviews …, 2013 - nature.com
The population of elderly individuals with rheumatoid arthritis (RA) is expanding, due mainly to increasing life expectancy. A variety of theories have been proposed to explain the ageing …
A Marchesoni, E Zaccara, R Gorla… - Annals of the New …, 2009 - Wiley Online Library
A cohort of rheumatoid arthritis (RA) patients in the Lombardy Rheumatology Network (LOHREN) registry and receiving anti‐TNF therapy was evaluated after 6, 12, 24, and 36 …
MA Blum, D Koo, JA Doshi - Clinical therapeutics, 2011 - Elsevier
BACKGROUND: Biologics are an important addition to the conventional care of patients with rheumatoid arthritis (RA). Poor persistence with and adherence to biologics can undermine …